Institute of Obstetrics and Gynecology of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, China.
Department of Reproductive Medicine, Second Affiliated Hospital, Jiangxi University of Chinese Medicine, Nanchang, China.
Am J Reprod Immunol. 2024 Aug;92(2):e13918. doi: 10.1111/aji.13918.
Zishen Qingre Lishi Huayu recipe (ZQLHR) has shown significant therapeutic effects in treating sex hormone levels and follicular developmental disorders in patients with polycystic ovary syndrome (PCOS). However, little is known about the potential mechanisms of its treatment.
Dehydroepiandrosterone and a high-fat diet induced the PCOS model rat. The serum of rats was collected to detect the levels of sex hormones and inflammatory cytokines by enzyme-linked immunosorbent assay, and the ovaries were collected for ovarian histopathology and qPCR assay to detect the levels of inflammatory cytokines in ovarian tissues. Granulosa cells (GCs) were collected for western blot assay to detect of IL-1β, IL-6R, and LOX protein expression levels.
ZQLHR could reduce body weight, regulate estrous cycles, and improve serum sex hormone levels, follicular development, and insulin resistance (IR) in PCOS model rats. In addition, ZQLHR treatment improved the levels of inflammatory cytokines in serum and ovary, and regulated the protein expression of IL-6R, IL-1β, and LOX in GCs of PCOS model rats. The results showed that the HOMA-IR index increased with the increasing levels of IL-6, IL-1β, and CRP, and decreased with the increased IL-10.
This study reveals that the treatment of endocrine disorders and ovulation disorders in PCOS with ZQLHR may be closely related to the improvement of systemic and ovarian inflammation in PCOS patients, as well as the inhibition of IL-6R, IL-1β, and LOX expression in GCs, which reemphasizes the role of reducing chronic inflammatory states in the treatment of PCOS. Moreover, this study reemphasizes the correlation between multiple inflammatory mediators and IR.
自拟滋阴清热利湿化瘀方（ZQLHR）在治疗多囊卵巢综合征（PCOS）患者的性激素水平和卵泡发育障碍方面显示出显著的治疗效果。然而，其治疗的潜在机制知之甚少。
用脱氢表雄酮和高脂饮食诱导 PCOS 模型大鼠。收集大鼠血清，用酶联免疫吸附试验检测性激素和炎性细胞因子水平，收集卵巢，进行卵巢组织病理学和 qPCR 检测，检测卵巢组织中炎性细胞因子水平。收集颗粒细胞（GCs），用 Western blot 检测 IL-1β、IL-6R 和 LOX 蛋白表达水平。
ZQLHR 可降低 PCOS 模型大鼠的体重，调节动情周期，改善血清性激素水平、卵泡发育和胰岛素抵抗（IR）。此外，ZQLHR 治疗可改善 PCOS 模型大鼠血清和卵巢中炎性细胞因子水平，并调节 GCs 中 IL-6R、IL-1β 和 LOX 的蛋白表达。结果表明，HOMA-IR 指数随 IL-6、IL-1β 和 CRP 水平的升高而升高，随 IL-10 水平的升高而降低。
本研究表明，ZQLHR 治疗 PCOS 的内分泌和排卵障碍可能与改善 PCOS 患者全身和卵巢炎症以及抑制 GCs 中 IL-6R、IL-1β 和 LOX 表达密切相关，再次强调了降低慢性炎症状态在 PCOS 治疗中的作用。此外，本研究再次强调了多种炎症介质与 IR 的相关性。
